Advertisement
Screener

Definium Therapeutics, Inc. (DFTX) Proceeds from Stock Options Exercised

2.8 / 5 stars · 68/120 Roast Me

Definium Therapeutics, Inc. Proceeds from Stock Options Exercised

Definium Therapeutics, Inc. (DFTX) reported Proceeds from Stock Options Exercised of $2.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-06

  • Definium Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $860.00K, a 786.60% increase year-over-year.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $1.20M, a 404.64% increase year-over-year.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $193.00K, a 328.89% increase year-over-year.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $98.00K, a 206.25% increase year-over-year.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for fiscal 2025 was $625.00K, a 12.71% decline from fiscal 2024.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for fiscal 2024 was $716.00K, a 1361.22% increase from fiscal 2023.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for fiscal 2023 was $49.00K, a 76.21% decline from fiscal 2022.
  • Definium Therapeutics, Inc. proceeds from stock options exercised for fiscal 2022 was $206.00K, a 96.40% decline from fiscal 2021.
Period endProceeds from Stock Options Exercised 3 monthProceeds from Stock Options Exercised 6 monthProceeds from Stock Options Exercised 9 monthProceeds from Stock Options Exercised 12 month
2026-06-30$860.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$2.06M
10-Q · filed 2026-08-06
$2.25M
derived: sum of 3 quarters · filed 2026-08-06
$2.35M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$1.20M
10-Q · filed 2026-05-07
$1.39M
derived: sum of 2 quarters · filed 2026-05-07
$1.49M
derived: sum of 3 quarters · filed 2026-05-07
$1.58M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$193.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$291.00K
derived: sum of 2 quarters · filed 2026-02-26
$388.00K
derived: sum of 3 quarters · filed 2026-08-06
$625.00K
10-K · filed 2026-02-26
2025-09-30$98.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$195.00K
derived: sum of 2 quarters · filed 2026-08-06
$432.00K
10-Q · filed 2025-11-06
$477.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$97.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$334.00K
10-Q · filed 2026-08-06
$379.00K
derived: sum of 3 quarters · filed 2026-08-06
$411.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$237.00K
10-Q · filed 2026-05-07
$282.00K
derived: sum of 2 quarters · filed 2026-05-07
$314.00K
derived: sum of 3 quarters · filed 2026-05-07
$488.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$45.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$77.00K
derived: sum of 2 quarters · filed 2026-02-26
$251.00K
derived: sum of 3 quarters · filed 2026-02-26
$716.00K
10-K · filed 2026-02-26
2024-09-30$32.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$206.00K
derived: sum of 2 quarters · filed 2025-11-06
$671.00K
10-Q · filed 2025-11-06
$720.00K
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$174.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
$639.00K
10-Q · filed 2025-07-31
$688.00K
derived: sum of 3 quarters · filed 2025-07-31
2024-03-31$465.00K
10-Q · filed 2025-05-08
$514.00K
derived: sum of 2 quarters · filed 2025-05-08
2023-12-31$49.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$49.00K
10-K · filed 2025-03-06
2023-09-30$0.00
10-Q · filed 2024-11-07
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$83.00K
derived: sum of 2 quarters · filed 2024-02-28
$83.00K
derived: sum of 3 quarters · filed 2024-02-28
$206.00K
10-K · filed 2024-02-28
2022-09-30$83.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$83.00K
derived: sum of 2 quarters · filed 2023-11-02
$206.00K
10-Q · filed 2023-11-02
$340.00K
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$123.00K
10-Q · filed 2023-08-03
$257.00K
derived: sum of 3 quarters · filed 2023-08-03
$572.00K
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31$123.00K
10-Q · filed 2023-05-04
$257.00K
derived: sum of 2 quarters · filed 2023-05-04
$572.00K
derived: sum of 3 quarters · filed 2023-05-04
$4.67M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$134.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
$449.00K
derived: sum of 2 quarters · filed 2023-03-09
$4.54M
derived: sum of 3 quarters · filed 2023-03-09
$5.72M
10-K · filed 2023-03-09
2021-09-30$315.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$4.41M
derived: sum of 2 quarters · filed 2022-11-10
$5.59M
10-Q · filed 2022-11-10
2021-06-30$4.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$5.27M
10-Q · filed 2022-08-11
2021-03-31$1.18M
10-Q · filed 2022-05-16
2020-12-31$648.00K
10-K · filed 2022-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cronos Group Inc. (CRON)$1.223B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B